Capillary electrophoresis–electrospray mass spectrometry and HR–ICP–MS for the detection and quantification of 10B-boronophenylalanine (10B–BPA) used in boron neutron capture therapy

2005 ◽  
Vol 384 (3) ◽  
pp. 751-760 ◽  
Author(s):  
Aurélien Pitois ◽  
Laura Aldave de las Heras ◽  
Antonella Zampolli ◽  
Luca Menichetti ◽  
Ramon Carlos ◽  
...  
Keyword(s):  
Mass Spectrometry ◽  
Capillary Electrophoresis ◽  
Boron Neutron Capture Therapy ◽  
Neutron Capture ◽  
Electrospray Mass Spectrometry ◽  
Neutron Capture Therapy ◽  
Boron Neutron Capture ◽  
Icp Ms ◽  
Detection And Quantification

scholarly journals A Study of The Assessment for Boron Neutron Capture Therapy Agent

2017 ◽  
Vol 2 (1) ◽  
pp. 9
Author(s):  
Isman Mulyadi Triatmoko ◽  
Sutjipto Sutjipto
Keyword(s):  
Cytotoxic Activity ◽  
Neutron Irradiation ◽  
Boron Neutron Capture Therapy ◽  
Neutron Capture ◽  
Neutron Capture Therapy ◽  
Glioblastoma Cells ◽  
Morphological Alterations ◽  
Boron Neutron Capture ◽  
Icp Ms ◽  
Biological Effectiveness

A study of the assessment criteria covers the synthesis and characterization of agent and test their biological effectiveness as boron neutron capture therapy (BNCT) agents in cancer treatment. The cellular uptake of this agent into the glioblastoma cells was assessed by boron analysis (ICP-MS) and by fluorescence imaging (confocal microscopy). The agent enters the glioblastoma cells exhibiting a similar profile, i.e., preferential accumulation in the cytoskeleton and membranes and a low cytotoxic activity (IC<sub>50</sub> values higher than 200 μM). The cytotoxic activity and cellular morphological alterations after neutron irradiation in the Research Reactor (&gt;10<sup>7</sup> neutrons cm<sup>−2</sup> s<sup>−1</sup>) were assessed by the MTT assay and by electron microscopy (TEM). Post neutron irradiation revealed that BNCT has a higher cytotoxic effect on the glioblastoma cells. Results provide a strong rationale for considering one of these compounds as a lead candidate for a new BNCT agent.

scholarly journals HGG-05. REGRESSION OF RECURRENT GLIOBLASTOMA AFTER BORON NEUTRON CAPTURE THERAPY AND CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY IN A CHILD

2020 ◽  
Vol 22 (Supplement_3) ◽  
pp. iii345-iii345
Author(s):  
Hsin-Hung Chen ◽  
Yi-Wei Chen
Keyword(s):  
T Cells ◽  
T Cell ◽  
Chimeric Antigen Receptor ◽  
Boron Neutron Capture Therapy ◽  
Neutron Capture ◽  
Antigen Receptor ◽  
Neutron Capture Therapy ◽  
T Cell Therapy ◽  
Boron Neutron Capture ◽  
Car T

Abstract A 6 y/o girl with recurrent multifocal glioblastoma received 3 times of boron neutron capture therapy (BNCT) and chimeric antigen receptor (CAR)–engineered T cells targeting the tumor-associated antigen HER2. Multiple infusions of CAR T cells were administered over 30 days through intraventricular delivery routes. It was not associated with any toxic effects of grade 3 or higher. After BNCT and CAR T-cell treatment, regression of all existing intracranial lesions were observed, along with corresponding increases in levels of cytokines and immune cells in the cerebrospinal fluid, but new lesions recurred soon after the treatment. This clinical response continued for 14 months after the initiation of first recurrence.

Nucleophilic radiosynthesis of boron neutron capture therapy-oriented PET probe [18F]FBPA using aryldiboron precursors

2021 ◽  
Author(s):  
Jing He ◽  
Heng Yan ◽  
Yanrong Du ◽  
Yan Ji ◽  
Fei Cai ◽  
...  
Keyword(s):  
Boron Neutron Capture Therapy ◽  
Neutron Capture ◽  
Neutron Capture Therapy ◽  
Boron Neutron Capture

A reliable copper-mediated nucleophilic radiosynthesis of the BNCT-oriented PET probe [18F]FBPA was developed using novel aryldiboron precursors.

Sign in / Sign up

Export Citation Format

Share Document